{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T19:11:45Z","timestamp":1760987505489,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["53\/17\/2003-BMSdt.12.03.2007"],"award-info":[{"award-number":["53\/17\/2003-BMSdt.12.03.2007"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009530","name":"Jawaharlal Institute of Postgraduate Medical Education and Research","doi-asserted-by":"publisher","award":["No.Edn.7(1)\/2010dt21.02.2011"],"award-info":[{"award-number":["No.Edn.7(1)\/2010dt21.02.2011"]}],"id":[{"id":"10.13039\/501100009530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s10549-020-05656-9","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T06:02:41Z","timestamp":1588917761000},"page":"147-158","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity"],"prefix":"10.1007","volume":"182","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8709-9159","authenticated-orcid":false,"given":"Gurusamy","family":"Umamaheswaran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dharanipragada","family":"Kadambari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh Kumar","family":"Muthuvel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sekar","family":"Kalaivani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaganathan","family":"Devi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solai Elango","family":"Damodaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh Chandra","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biswajit","family":"Dubashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven Aibor","family":"Dkhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandrasekaran","family":"Adithan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,8]]},"reference":[{"issue":"24","key":"5656_CR1","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/nejmra023246","volume":"348","author":"IE Smith","year":"2003","unstructured":"Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348(24):2431\u20132442. https:\/\/doi.org\/10.1056\/nejmra023246","journal-title":"N Engl J Med"},{"issue":"26","key":"5656_CR2","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1056\/nejmoa052258","volume":"353","author":"B Thurlimann","year":"2005","unstructured":"Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353(26):2747\u20132757. https:\/\/doi.org\/10.1056\/nejmoa052258","journal-title":"N Engl J Med"},{"issue":"12","key":"5656_CR3","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1200\/jco.2007.12.6334","volume":"26","author":"HB Muss","year":"2008","unstructured":"Muss HB, Tu D, Ingle JN, Martino S, Robert NJ, Pater JL, Whelan TJ, Palmer MJ, Piccart MJ, Shepherd LE, Pritchard KI, He Z, Goss PE (2008) Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole-placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA17. J Clin Oncol 26(12):1956\u20131964. https:\/\/doi.org\/10.1200\/jco.2007.12.6334","journal-title":"J Clin Oncol"},{"issue":"1","key":"5656_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/gco.0b013e328334e44e","volume":"22","author":"JE Mortimer","year":"2010","unstructured":"Mortimer JE (2010) Managing the toxicities of the aromatase inhibitors. Curr Opin Obstet Gynecol 22(1):56\u201360. https:\/\/doi.org\/10.1097\/gco.0b013e328334e44e","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"9348","key":"5656_CR5","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/s0140-6736(02)11774-0","volume":"360","author":"V Stearns","year":"2002","unstructured":"Stearns V, Ullmer L, Lopez JF, Smith Y, Isaacs C, Hayes D (2002) Hot flushes. Lancet 360(9348):1851\u20131861. https:\/\/doi.org\/10.1016\/s0140-6736(02)11774-0","journal-title":"Lancet"},{"issue":"3","key":"5656_CR6","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.breast.2007.01.011","volume":"16","author":"HJ Burstein","year":"2007","unstructured":"Burstein HJ (2007) Aromatase inhibitor-associated arthralgia syndrome. Breast 16(3):223\u2013234. https:\/\/doi.org\/10.1016\/j.breast.2007.01.011","journal-title":"Breast"},{"issue":"1","key":"5656_CR7","doi-asserted-by":"publisher","first-page":"R8","DOI":"10.1186\/bcr2813","volume":"13","author":"JJ Mao","year":"2011","unstructured":"Mao JJ, Su HI, Feng R, Donelson ML, Aplenc R, Stanczyk RTR, F, DeMichele A, (2011) Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. Breast Cancer Res 13(1):R8. https:\/\/doi.org\/10.1186\/bcr2813","journal-title":"Breast Cancer Res"},{"issue":"4","key":"5656_CR8","first-page":"430","volume":"51","author":"R Milczarek","year":"2005","unstructured":"Milczarek R, Klimek J (2005) Aromatase\u2014key enzyme of estrogen biosynthesis. Postepy Biochem 51(4):430\u2013439","journal-title":"Postepy Biochem"},{"key":"5656_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12916-015-0373-9","volume":"13","author":"O Artigal\u00e1s","year":"2015","unstructured":"Artigal\u00e1s O, Vanni T, Hutz MH, Ashton-Prolla P, Schwartz IV (2015) Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis. BMC Med 13:139. https:\/\/doi.org\/10.1186\/s12916-015-0373-9","journal-title":"BMC Med"},{"issue":"23","key":"5656_CR10","doi-asserted-by":"publisher","first-page":"11071","DOI":"10.1158\/0008-5472.can-05-1218","volume":"65","author":"CX Ma","year":"2005","unstructured":"Ma CX, Adjei AA, Salavaggione OE, Coronel J, Pelleymounter L, Wang L, Eckloff BW, Schaid D, Wieben ED, Adjei AA, Weinshilboum RM (2005) Human aromatase: gene resequencing and functional genomics. Cancer Res. 65(23):11071\u201311082. https:\/\/doi.org\/10.1158\/0008-5472.can-05-1218","journal-title":"Cancer Res."},{"issue":"3","key":"5656_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/jhg.2010.6","volume":"55","author":"SJ Lee","year":"2010","unstructured":"Lee SJ, Kim WY, Choi JY, Lee SS, Shin JG (2010) Identification of CYP19A1 single-nucleotide polymorphisms and their haplotype distributions in a Korean population. J Hum Genet 55(3):189\u2013193. https:\/\/doi.org\/10.1038\/jhg.2010.6","journal-title":"J Hum Genet"},{"issue":"3","key":"5656_CR12","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s12032-013-0665-x","volume":"30","author":"G Umamaheswaran","year":"2013","unstructured":"Umamaheswaran G, Dkhar SA, Kalaivani S, Anjana R, Revathy M, Jaharamma M, Shree KM, Kadambari D, Adithan C (2013) Haplotype structures and functional polymorphic variants of the drug target enzyme aromatase (CYP19A1) in South Indian population. Med Oncol 30(3):665. https:\/\/doi.org\/10.1007\/s12032-013-0665-x","journal-title":"Med Oncol"},{"issue":"2","key":"5656_CR13","doi-asserted-by":"publisher","first-page":"e0117347","DOI":"10.1371\/journal.pone.0117347","volume":"10","author":"A Starlard-Davenport","year":"2015","unstructured":"Starlard-Davenport A, Orloff MS, Dhakal I, Penney RB, Kadlubar SA (2015) Genotypic and allelic variability in CYP19A1 among populations of African and European ancestry. PLoS ONE 10(2):e0117347. https:\/\/doi.org\/10.1371\/journal.pone.0117347","journal-title":"PLoS ONE"},{"issue":"3","key":"5656_CR14","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1158\/1078-0432.ccr-07-1923","volume":"14","author":"R Colomer","year":"2008","unstructured":"Colomer R, Monzo M, Tusquets I, Rifa J, Baena JM, Barnadas A, Calvo L, Carabantes F, Crespo C, Munoz M, Llombart A, Plazaola A, Artells R, Gilabert M, Lloveras B, Alba E (2008) A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin Cancer Res 14(3):811\u2013816. https:\/\/doi.org\/10.1158\/1078-0432.ccr-07-1923","journal-title":"Clin Cancer Res"},{"issue":"5","key":"5656_CR15","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s00280-011-1615-y","volume":"68","author":"IH Park","year":"2011","unstructured":"Park IH, Lee YS, Lee KS, Kim SY, Hong SH, Jeong J, Lee H, Ro J, Nam BH (2011) Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer. Cancer Chemother Pharmacol 68(5):1263\u20131271. https:\/\/doi.org\/10.1007\/s00280-011-1615-y","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"5656_CR16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.bone.2013.04.021","volume":"55","author":"N Napoli","year":"2013","unstructured":"Napoli N, Rastelli A, Ma C, Yarramaneni J, Vattikutti S, Moskowitz G, Giri T, Mueller C, Kulkarny V, Qualls C, Ellis M, Armamento-Villareal R (2013) Genetic polymorphisms at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER (+) breast cancer. Bone 55(2):309\u2013314. https:\/\/doi.org\/10.1016\/j.bone.2013.04.021","journal-title":"Bone"},{"issue":"3","key":"5656_CR17","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s10549-013-2504-3","volume":"138","author":"NL Henry","year":"2014","unstructured":"Henry NL, Skaar TC, Dantzer J, Li L, Kidwell K, Gersch C, Nguyen AT, Rae JM, Desta Z, Oesterreich S, Phillips S, Carpenter JS, Storniolo AM, Stearns V, Hayes DF, Flockhart DA (2014) Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer. Breast Cancer Res Treat 138(3):807\u2013816. https:\/\/doi.org\/10.1007\/s10549-013-2504-3","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"5656_CR18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s10549-013-2638-3","volume":"140","author":"N Garcia-Giralt","year":"2013","unstructured":"Garcia-Giralt N, Rodriguez-Sanz M, Prieto-Alhambra D, Servitja S, Torres-Del Pliego ET, Balcells S, Albanell J, Grinberg D, Diez-Perez A, Tusquets I, Nogues X (2013) Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study. Breast Cancer Res Treat 140(2):385\u2013395. https:\/\/doi.org\/10.1007\/s10549-013-2638-3","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"5656_CR19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10549-015-3378-3","volume":"151","author":"B Leyland-Jones","year":"2015","unstructured":"Leyland-Jones B, Gray KP, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dellorto P, Biasi MO, Th\u00fcrlimann B, Lyng MB, Ditzel HJ, Harvey VJ, Neven P, Treilleux I, Rasmussen BB, Maibach R, Price KN, Coates AS, Goldhirsch A, Pagani O, Viale G, Rae JM, Regan MM (2015) CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1\u201398 trial. Breast Cancer Res Treat 151(2):373\u2013384. https:\/\/doi.org\/10.1007\/s10549-015-3378-3","journal-title":"Breast Cancer Res Treat"},{"key":"5656_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejca.2015.12.013","volume":"56","author":"A Lintermans","year":"2016","unstructured":"Lintermans A, Van Asten K, Jongen L, Van Brussel T, Laenen A, Verhaeghe J, Vanderschueren D, Lambrechts D, Neven P (2016) Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients. Eur J Cancer 56:31\u201336. https:\/\/doi.org\/10.1016\/j.ejca.2015.12.013","journal-title":"Eur J Cancer"},{"issue":"31","key":"5656_CR21","doi-asserted-by":"publisher","first-page":"4674","DOI":"10.1200\/jco.2010.28.5064","volume":"28","author":"JN Ingle","year":"2010","unstructured":"Ingle JN, Schaid DJ, Goss PE, Liu M, Mushiroda T, Chapman JA, Kubo M, Jenkins GD, Batzler A, Shepherd L, Pater J, Wang L, Ellis MJ, Stearns V, Rohrer DC, Goetz MP, Pritchard KI, Flockhart DA, Nakamura Y, Weinshilboum RM (2010) Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 28(31):4674\u20134682. https:\/\/doi.org\/10.1200\/jco.2010.28.5064","journal-title":"J Clin Oncol"},{"issue":"1","key":"5656_CR22","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.etap.2014.10.022","volume":"39","author":"G Umamaheswaran","year":"2015","unstructured":"Umamaheswaran G, Kadambari D, Kumar AS, Revathy M, Anjana R, Adithan C, Dkhar SA (2015) Polymorphic genetic variations of cytochrome P450 19A1 and T-cell leukemia 1A genes in the Tamil population. Environ Toxicol Pharmacol 39(1):102\u2013113. https:\/\/doi.org\/10.1016\/j.etap.2014.10.022","journal-title":"Environ Toxicol Pharmacol"},{"issue":"5","key":"5656_CR23","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1530\/eje.0.1480519","volume":"148","author":"A Enjuanes","year":"2003","unstructured":"Enjuanes A, Garcia-Giralt N, Supervia A, Nogu\u00e9s X, Mellibovsky L, Carbonell J, Grinberg D, Balcells S, Diez-Perez A (2003) Regulation of CYP19 gene expression in primary human osteoblasts: effects of vitamin D and other treatments. Eur J Endocrinol 148(5):519\u2013526. https:\/\/doi.org\/10.1530\/eje.0.1480519","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"5656_CR24","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1530\/eje.1.02032","volume":"153","author":"A Enjuanes","year":"2005","unstructured":"Enjuanes A, Garcia-Giralt N, Superv\u00eda A, Nogu\u00e9s X, Ruiz-Gasp\u00e0 S, Bustamante M, Mellibovsky L, Grinberg D, Balcells S, Diez-Perez A (2005) Functional analysis of the I.3, I.6, pII and I.4 promoters of CYP19 (aromatase) gene in human osteoblasts and their role in vitamin D and dexamethasone stimulation. Eur J Endocrinol 153(6):981\u2013988. https:\/\/doi.org\/10.1530\/eje.1.02032","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"5656_CR25","doi-asserted-by":"publisher","first-page":"18973","DOI":"10.3390\/ijms140918973","volume":"14","author":"L Liu","year":"2013","unstructured":"Liu L, Bai Y, Zhou J, Sun X, Sui H, Zhang WJ, Yuan HH, Xie R, Wei XL, Zhang TT, Huang P, Li YJ, Wang JX, Zhao S, Zhang QY (2013) A polymorphism at the 3\u2019-UTR region of the aromatase gene is associated with the efficacy of the aromatase inhibitor, anastrozole, in metastatic breast carcinoma. Int J Mol Sci 14(9):18973\u201318988. https:\/\/doi.org\/10.3390\/ijms140918973","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5656_CR26","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13058-016-0771-8","volume":"18","author":"H Johansson","year":"2016","unstructured":"Johansson H, Gray KP, Pagani O, Regan MM, Viale G, Aristarco V, Macis D, Puccio A, Roux S, Maibach R, Colleoni M, Rabaglio M, Price KN, Coates AS, Gelber RD, Goldhirsch A, Kammler R, Bonanni B, Walley BA (2016) Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. Breast Cancer Res Treat. 18(1):110. https:\/\/doi.org\/10.1186\/s13058-016-0771-8","journal-title":"Breast Cancer Res Treat."},{"issue":"2","key":"5656_CR27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10549-015-3608-8","volume":"154","author":"S Oesterreich","year":"2015","unstructured":"Oesterreich S, Henry NL, Kidwell KM, Van Poznak CH, Skaar TC, Dantzer J, Li L, Hangartner TN, Peacock M, Nguyen AT, Rae JM, Desta Z, Philips S, Storniolo AM, Stearns V, Hayes DF (2015) Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover. Breast Cancer Res Treat 154(2):263\u2013273. https:\/\/doi.org\/10.1007\/s10549-015-3608-8","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"5656_CR28","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10549-014-2873-2","volume":"144","author":"DBY Fontein","year":"2014","unstructured":"Fontein DBY, Houtsma D, Norteir JWR, Baak-Pablo RF, Kranenbarg EM, van der Straaten TR, Putter H, Seynaeve C, Gelderblom H, van de Velde CJ, Guchelaar HJ (2014) Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial. Breast Cancer Res Treat 144(3):599\u2013606. https:\/\/doi.org\/10.1007\/s10549-014-2873-2","journal-title":"Breast Cancer Res Treat"},{"issue":"25","key":"5656_CR29","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1200\/jco.2007.10.7573","volume":"25","author":"KD Crew","year":"2007","unstructured":"Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25(25):3877\u20133883. https:\/\/doi.org\/10.1200\/jco.2007.10.7573","journal-title":"J Clin Oncol"},{"issue":"2","key":"5656_CR30","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10549-007-9774-6","volume":"111","author":"NL Henry","year":"2008","unstructured":"Henry NL, Giles JT, Ang D, Mohan M, Dadabhoy D, Robarge J, Hayden J, Lemler S, Shahverdi K, Powers P, Li L, Flockhart D, Stearns V, Hayes DF, Storniolo AM, Clauw DJ (2008) Prospective characterization of musculoskeletal symptoms in early-stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 111(2):365\u2013372. https:\/\/doi.org\/10.1007\/s10549-007-9774-6","journal-title":"Breast Cancer Res Treat"},{"issue":"16","key":"5656_CR31","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1002\/cncr.24419","volume":"115","author":"JJ Mao","year":"2009","unstructured":"Mao JJ, Stricker C, Bruner D, Xie S, Bowman MA, Farrar JT, Greene BT, DeMichele A (2009) Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 115(16):3631\u20133639. https:\/\/doi.org\/10.1002\/cncr.24419","journal-title":"Cancer"},{"issue":"1","key":"5656_CR32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.breast.2011.09.001","volume":"21","author":"S Servitja","year":"2012","unstructured":"Servitja S, Nogues X, Prieto-Alhambra D, Mart\u00ednez-Garc\u00eda M, Garrig\u00f3s L, Pe\u00f1a MJ, de Ramon M, D\u00edez-P\u00e9rez A, Albanell J, Tusquets I (2012) Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer. Breast 21(1):95\u2013101. https:\/\/doi.org\/10.1016\/j.breast.2011.09.001","journal-title":"Breast"},{"issue":"3","key":"5656_CR33","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1200\/jco.2002.20.3.751","volume":"20","author":"J Geisler","year":"2002","unstructured":"Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE (2002) Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20(3):751\u2013757. https:\/\/doi.org\/10.1200\/jco.2002.20.3.751","journal-title":"J Clin Oncol"},{"issue":"1","key":"5656_CR34","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1158\/0008-5472.can-09-3224","volume":"70","author":"L Wang","year":"2010","unstructured":"Wang L, Ellsworth KA, Moon I, Pelleymounter LL, Eckloff BW, Martin Fridley BL, Jenkins GD, Batzler A, Suman VJ, Ravi S, Dixon JM, Miller WR, Wieben ED, Buzdar A, Weinshilboum RM, Ingle JN (2010) Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res 70(1):319\u2013328. https:\/\/doi.org\/10.1158\/0008-5472.can-09-3224","journal-title":"Cancer Res"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05656-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-020-05656-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05656-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T01:10:02Z","timestamp":1620436202000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-020-05656-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,8]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["5656"],"URL":"https:\/\/doi.org\/10.1007\/s10549-020-05656-9","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2020,5,8]]},"assertion":[{"value":"20 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was performed in human participants following the Declaration of Helsinki and its amendments. Research protocols were approved by the Institutional Scientific Advisory and Research Ethics Committees of JIPMER.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all the subjects who participated in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}